ABOUT COMPANY BIRD PETS CATTLE PIG BREEDING DISTRIBUTORS HOME NEWS WE ARE IN THE WORLD CONTACTS Login Register 10 June 2015 Prevention of Dermacentor reticulatus transmission of Babesia canis to dogs treated with fluralaner chewable tablets (Bravecto ™) abstract General information. The prophylactic effect of fluralaner chewable tablets (Bravecto ™) against the transmission of Babesia canis by Dermacentor reticulatus ticks was evaluated . Methods.16 dogs negative by PCR and indirect immunofluorescence test (IFAT) for B. canis were divided into two groups. On day 0, dogs in one group (n = 8) received one oral dose of Bravecto ™ chewable tablets (active ingredient fluralaner) according to the instructions for use, while dogs in the control group (n = 8) received no treatment. On days 2, 28, 56, 70 and 84, dogs were infected with 50 (± 4) D. reticulatus ticks infected with B. canis, and 48 ± 4 hours after infection, the number of ticks was determined directly on the animals by spreading the hair with the fingers. Before each infection, the presence of B. canis in the ticks was confirmed by PCR. On day 90, ticks were counted and removed from all dogs. The anti-mite efficacy was calculated for each time point when the assessment was made. After treatment, all dogs underwent a physical examination, with blood samples taken for PCR every 7 days, blood samples for IFAT every 14 days, and rectal temperature measured three times a week. Dogs showing symptoms of babesiosis or positive PCR test results were given a blood smear to find babesia in red blood cells, and upon confirmation of the diagnosis, treatment was prescribed, and the dog, in this case, was replaced with a spare. The prophylactic effect was assessed by comparing the number of infected dogs in the treated group with the number of infected dogs in the untreated control group. who showed symptoms of babesiosis or positive results of PCR analysis, a blood smear was taken to find babesia in erythrocytes, and when the diagnosis was confirmed, treatment was prescribed, and the dog, in this case, was replaced with a spare. The prophylactic effect was assessed by comparing the number of infected dogs in the treated group with the number of infected dogs in the untreated control group. who showed symptoms of babesiosis or positive results of PCR analysis, a blood smear was taken to find babesia in erythrocytes, and when the diagnosis was confirmed, treatment was prescribed, and the dog, in this case, was replaced with a spare. The prophylactic effect was assessed by comparing the number of infected dogs in the treated group with the number of infected dogs in the untreated control group. Results. All control dogs were infected with B. canis as confirmed by PCR and IFAT. None of the 8 treated dogs became infected with B. canis, as IFAT and PCR results remained negative throughout the study until day 112. The fluralaner chewable tablet showed 100% efficacy against ticks on days 4, 30, 58 and 90, and on days 72 and 86, the efficacy was 99.6% and 99.2%, respectively. During the 12 weeks of the study, a 100% prophylactic effect on transmission of B. canis was shown. All control dogs were infected with B. canis as confirmed by PCR and IFAT. None of the 8 treated dogs became infected with B. canis , as IFAT and PCR results remained negative throughout the study until day 112. The fluralaner chewable tablet showed 100% efficacy against ticks on days 4, 30, 58 and 90, and on days 72 and 86, the efficacy was 99.6% and 99.2%, respectively. During the 12 weeks of the study, a 100% prophylactic effect on transmission of B. canis was shown . Download full article (Download PDF) © 2009-2017 MSD Animal Health Site Map